OALib Journal期刊
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE？) antibody construct, in patients with refractory solid tumors
DOI: 10.1080/2162402X.2018.1450710
Andrea Kratzer ,
Annette Hasenburg ,
Barbara Ritter ,
Beate Rautenberg ,
Djordje Atanackovic ,
Dorothea Wessiepe ,
Eva Vieser ,
Ingrid Patzak ,
James B. Rottman ,
Marie-Elisabeth Goebeler ,
Martin Wolf ,
Matthias Friedrich ,
Maxim Kebenko ,
Ruth Seggewiss-Bernhardt ,
Sabine Stienen ,
Stefanie Elm ,
Walter Fiedler Keywords: AMG 110 , solitomab , MT110 , immunotherapy , bispecific , BiTE？ , EpCAM , phase 1 , solid tumor , CD3
Abstract:
Full-Text
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
